TABLE 5
FROM:
Effect of high dose ramipril with or without indomethacin on glomerular selectivity
Roberto Pisoni, Piero Ruggenenti, Fabio Sangalli, Maria Serena Lepre, Andrea Remuzzi and Giuseppe Remuzzi
BACK TO ARTICLETable 5. Serum potassium, total and high-density lipoprotein (HDL) cholesterol, and triglycerides at baseline, at the end of the ramipril titration phase (titration) at the maximum-tolerated ramipril dose (MR), at the indomethacin plus maximum-tolerated ramipril dose (MR+Ind), and after recovery
| Baseline | Titration | MR | MR+Ind | Recovery | |
|---|---|---|---|---|---|
| Serum potassium mEq/L | 4.2 0.5 | 4.40.6 | 4.50.4 | 4.80.5a
b
c
| 4.40.4 |
| Serum total cholesterol mg/dL | 27796 | 291108c
| 279101 | 267112b
c
| 313134 |
| Serum HDL cholesterol mg/dL | 53.414.5 | 55.318.8 | 51.917.2 | 52.414.6 | 56.313.8 |
| Serum triglycerides mg/dL | 18899 | 183137 | 199137 | 178124 | 213142 |
Data are mean SD.
a P < 0.01 vs. baseline
b P < 0.05 vs. titration
c P < 0.05 vs. recovery
